kat6 inhibitor men2312
Generic: KAT6 Inhibitor MEN2312
kat6 inhibitor men2312: 1 clinical trial tracked.
kat6 inhibitor men2312 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about kat6 inhibitor men2312, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer
Primary endpoint: Number of Participants Experiencing Dose-limiting Toxicity When Administered MEN2312
InterventionalRandomizedopen240 targetStarted 2024-10Completion 2026-1042 sites · Spain, United StatesStemline Therapeutics, Inc.